These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 37348110)

  • 1. Urinary retention and mydriasis secondary to topical glycopyrronium for axillary hyperhidrosis.
    Green HH; Ray L; Buchanan J; Matsler N
    Am J Health Syst Pharm; 2023 Sep; 80(18):1234-1237. PubMed ID: 37348110
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A 44-Week Open-Label Study Evaluating Safety and Efficacy of Topical Glycopyrronium Tosylate in Patients with Primary Axillary Hyperhidrosis.
    Glaser DA; Hebert AA; Nast A; Werschler WP; Green L; Mamelok RD; Quiring J; Drew J; Pariser DM
    Am J Clin Dermatol; 2019 Aug; 20(4):593-604. PubMed ID: 31111409
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Limited Systemic Exposure with Topical Glycopyrronium Tosylate in Primary Axillary Hyperhidrosis.
    Pariser DM; Lain EL; Mamelok RD; Drew J; Mould DR
    Clin Pharmacokinet; 2021 May; 60(5):665-676. PubMed ID: 33433785
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mydriasis and anisocoria in a pediatric hyperhidrosis patient with interesting findings in the family cat.
    Sandhu M; Eisenstein K
    Pediatr Dermatol; 2023 Jan; 40(1):210-211. PubMed ID: 36263444
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Topical glycopyrronium tosylate in Japanese patients with primary axillary hyperhidrosis: A randomized, double-blind, vehicle-controlled study.
    Yokozeki H; Fujimoto T; Wanatabe S; Ogawa S; Fujii C
    J Dermatol; 2022 Jan; 49(1):86-94. PubMed ID: 34636057
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacologic Mydriasis Secondary to Topical Glycopyrronium Tosylate Cloths: Clinical Characterization From a Multicenter Analysis.
    Kaufman AR; Gulati S; Pula JH; Janetos TM; Cherayil NR; Chiu E; Shepherd EA; Golnik KC; Garcia-Valenzuela E; MacIntosh PW; Johnson BT; Curnyn KM
    J Neuroophthalmol; 2022 Dec; 42(4):530-534. PubMed ID: 35427257
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term efficacy and safety of topical glycopyrronium tosylate for the treatment of primary axillary hyperhidrosis: Post hoc pediatric subgroup analysis from a 44-week open-label extension study.
    Hebert AA; Glaser DA; Green L; Hull C; Cather J; Drew J; Gopalan R; Pariser DM
    Pediatr Dermatol; 2020 May; 37(3):490-497. PubMed ID: 32147881
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A new medication, a new toxidrome - A case report of anticholinergic wipe toxicity due to improper medication use.
    Michael T; Paul C
    Am J Emerg Med; 2021 Aug; 46():797.e1-797.e2. PubMed ID: 33583621
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Glycopyrronium Tosylate (Qbrexza) for Hyperhidrosis.
    Nwannunu CE; Limmer AL; Coleman K; Shah R; Patel RR; Mui UN; Tyring SK
    Skin Therapy Lett; 2019 Mar; 24(2):1-3. PubMed ID: 30970203
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Topical glycopyrronium tosylate for the treatment of primary axillary hyperhidrosis: Results from the ATMOS-1 and ATMOS-2 phase 3 randomized controlled trials.
    Glaser DA; Hebert AA; Nast A; Werschler WP; Green L; Mamelok R; Drew J; Quiring J; Pariser DM
    J Am Acad Dermatol; 2019 Jan; 80(1):128-138.e2. PubMed ID: 30003988
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Topical Glycopyrronium Tosylate for the Treatment of Primary Axillary Hyperhidrosis: Patient-Reported Outcomes from the ATMOS-1 and ATMOS-2 Phase III Randomized Controlled Trials.
    Pariser DM; Hebert AA; Drew J; Quiring J; Gopalan R; Glaser DA
    Am J Clin Dermatol; 2019 Feb; 20(1):135-145. PubMed ID: 30378087
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Glycopyrronium tosylate in pediatric primary axillary hyperhidrosis: Post hoc analysis of efficacy and safety findings by age from two phase three randomized controlled trials.
    Hebert AA; Glaser DA; Green L; Werschler WP; Forsha DW; Drew J; Gopalan R; Pariser DM
    Pediatr Dermatol; 2019 Jan; 36(1):89-99. PubMed ID: 30451318
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Use of gloves when applying topical glycopyrronium for treatment of primary axillary hyperhidrosis.
    Siscos SM; Figenshau K; Rajpara A
    J Am Acad Dermatol; 2020 Oct; 83(4):e275. PubMed ID: 31846717
    [No Abstract]   [Full Text] [Related]  

  • 14. Topical Glycopyrronium Tosylate in Primary Axillary Hyperhidrosis: A Profile of Its Use.
    Lamb YN
    Clin Drug Investig; 2019 Nov; 39(11):1141-1147. PubMed ID: 31571127
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anisocoria secondary to antiperspirant wipes in a pediatric population: a case series.
    Pecha JD; Yen KG; Moisiuc A; Cantor A
    J AAPOS; 2022 Feb; 26(1):42-43. PubMed ID: 34798293
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Urinary retention caused by topical glycopyrrolate for hyperhidrosis.
    Madan V; Beck MH
    Br J Dermatol; 2006 Sep; 155(3):634-5. PubMed ID: 16911300
    [No Abstract]   [Full Text] [Related]  

  • 17. Dilated pupils caused by topical glycopyrrolate for hyperhidrosis.
    Panting KJ; Alkali AS; Newman WD; Sharpe GR
    Br J Dermatol; 2008 Jan; 158(1):187-8. PubMed ID: 17944977
    [No Abstract]   [Full Text] [Related]  

  • 18. Pharmacologic anisocoria secondary to topical glycopyrronium for axillary hyperhidrosis: an emerging clinical presentation.
    Kaufman AR; Gulati S; Curnyn KM
    Can J Ophthalmol; 2020 Oct; 55(5):464. PubMed ID: 32735775
    [No Abstract]   [Full Text] [Related]  

  • 19. Use of oral glycopyrronium bromide in hyperhidrosis.
    Bajaj V; Langtry JA
    Br J Dermatol; 2007 Jul; 157(1):118-21. PubMed ID: 17459043
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mydriasis secondary to use of glycopyrrolate cream.
    Radotra A; Baneke A; Paul B
    Br J Hosp Med (Lond); 2019 Dec; 80(12):736. PubMed ID: 31822169
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.